Tempest Therapeutics (NASDAQ:TPST) Announces Quarterly Earnings Results

Tempest Therapeutics (NASDAQ:TPST) posted its quarterly earnings results on Monday. The company reported ($0.62) earnings per share for the quarter, meeting the consensus estimate of ($0.62), FiscalAI reports.

Tempest Therapeutics Trading Up 7.9%

NASDAQ TPST opened at $1.64 on Wednesday. The company has a market cap of $8.09 million, a P/E ratio of -0.25 and a beta of -2.42. The company has a fifty day simple moving average of $2.33 and a 200 day simple moving average of $5.14. Tempest Therapeutics has a 12-month low of $1.50 and a 12-month high of $12.23.

Insiders Place Their Bets

In other Tempest Therapeutics news, CEO Matthew Angel acquired 231,482 shares of the company’s stock in a transaction on Tuesday, March 24th. The shares were purchased at an average cost of $2.16 per share, with a total value of $500,001.12. Following the completion of the purchase, the chief executive officer owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.28% of the company’s stock.

Institutional Investors Weigh In On Tempest Therapeutics

A hedge fund recently bought a new stake in Tempest Therapeutics stock. Dimensional Fund Advisors LP bought a new position in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 11,444 shares of the company’s stock, valued at approximately $33,000. Dimensional Fund Advisors LP owned about 0.23% of Tempest Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempest Therapeutics in a research report on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Tempest Therapeutics currently has a consensus rating of “Reduce” and an average target price of $12.50.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.